QTc Time Correlates with Amitriptyline and Venlafaxine Serum Levels in Elderly Psychiatric Inpatients.
Journal
Pharmacopsychiatry
ISSN: 1439-0795
Titre abrégé: Pharmacopsychiatry
Pays: Germany
ID NLM: 8402938
Informations de publication
Date de publication:
Jan 2019
Jan 2019
Historique:
pubmed:
22
2
2018
medline:
7
2
2019
entrez:
22
2
2018
Statut:
ppublish
Résumé
Many antidepressants cause QT prolongation but the classification of cardiac risk of these drugs varies markedly in different published lists. This retrospective study analyzed the correlation of QTc time with amitriptyline and venlafaxine serum level in elderly psychiatric inpatients. Elderly inpatients aged≥65 years for whom venlafaxine or amitriptyline serum level had been measured were selected retrospectively from a therapeutic drug monitoring database and screened for an electrocardiogram measurement at the time of blood withdrawal. The correlation of amitriptyline or venlafaxine serum levels with QTc time was examined by using Pearson's correlation analysis. Amitriptyline serum levels (n=11) correlated significantly with QTc time (r=0.918, p<0.001, CI 95%). Venlafaxine serum levels (n=27) also correlated significantly with QTc time (r=0.382, p<0.05, CI 95%). Amitriptyline and venlafaxine induce QT prolongation depending on drug concentrations in blood. Its extent, however, is very low when drug serum levels are within the therapeutic range. Future pharmacokinetic studies that correlate drug serum level and QT time should classify the cardiac risk of drugs based on the grade of the regression line in relation to the therapeutic range.
Identifiants
pubmed: 29466824
doi: 10.1055/s-0044-102009
doi:
Substances chimiques
Antidepressive Agents
0
Amitriptyline
1806D8D52K
Venlafaxine Hydrochloride
7D7RX5A8MO
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
38-43Informations de copyright
© Georg Thieme Verlag KG Stuttgart · New York.
Déclaration de conflit d'intérêts
Christoph Hiemke has received speaker’s and consultancy fees from Janssen, Stada, and Servier. He is managing director of the psiac GmbH (www.psiac.de), which provides an Internet-based drug-drug interaction program. He reports no conflict of interest with this publication. All other authors declare no conflicts of interest as well. The research study did not receive funds or support from any source.